Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

Release Date: February 28, 2018
Expiration Date: February 28, 2019
Media: Internet - based


Activity Overview

Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application features case-based discussion of the application of immune-based therapies in several tumor types. Interactive clinical vignettes are followed by short video interviews with leading oncology experts and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians using immunotherapy.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

CME/CE Activity Table of Contents

  • Module 1. Acute Lymphoblastic Leukemia
  • Module 2. Melanoma
  • Module 3. Immune-Related Adverse Events
  • Module 4. Renal Cell Carcinoma
  • Module 5. Non–Small Cell Lung Cancer

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the immunotherapies and their evolving roles in the treatment of cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain current and evolving mechanistic approaches regarding how the immune system can be targeted in the treatment of cancer
  • Evaluate clinical trial findings on immuno-oncology strategies, and how they can be practically applied to the management of cancer in multiple lines of care
  • Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies
  • Describe how common and uncommon adverse events associated with the use of immuno-oncology strategies can be proactively mitigated and managed
  • Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials that are evaluating emerging immuno-oncology strategies

Faculty, Staff, and Planners' Disclosures


Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Chair, Melanoma Committee at SWOG
Los Angeles, CA

Disclosure: Consultant: Merck, Novartis, Roche; Shareholder: Abraxis, CytomX, Compugen, Five Prime Therapeutics, Kite Pharma


David F. McDermott, MD
Leader, Dana-Farber Harvard Cancer Institute
Kidney Cancer Program
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosure: Grant/Research Support: Prometheus Laboratories; Consultant: Bristol-Myers Squibb, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharma, Genentech

David L. Porter, MD
Jodi Fisher Horowitz Professor in Leukemia Care Excellence
Director, Blood and Marrow Transplantation
Hospital of the University of Pennsylvania
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure: Grant/Research Support: Novartis Research Support; Consultant: Novartis, Kite Pharma, Servier (advisory board); Shareholder: Roche

Naiyer A. Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY

Disclosure: Consultant: Merck, Roche, Bristol-Myers Squibb, AstraZeneca, ARMO BioSciences; Shareholder: Gritstone Oncology

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By